TrialBMC cancer2024

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.

Byoung Chul Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.